Talis Biomedical Corporation (TLIS)
Talis Biomedical Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $2.84, up 0.00% on the session, giving a market capitalisation of $5.2M. On trailing twelve-month figures it carries a trailing P/E of -0.08, a net margin of -15050.2%. Its beta of 1.32 implies it has historically moved more than the broad market.
Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually transmitted infections. Its pipeline further includes other diagnostic tests for various respiratory pathogens, such as a panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus. Established in 2013, Talis Biomedical Corporation is headquartered in Menlo Park, California.
Talis Biomedical Corporation is most often compared with the following Healthcare names: